IGF2 and cancer: This is also consistent with the retrospective literature findings conveyed herein (Table 1 and Figure 1) supporting the idea that IGF2 transcript or IGF-II protein expression is a broader event in cancer compared to the established but rarer paraneoplastic hypoglycemic symptoms linked to IGF-II’s non-suppressible insulin-like activity (NSILA) [1], also referred as non-islet-cell tumor hypoglycemia (NICTH) [8] and extra-pancreatic tumor hypoglycemia (EPTH) [32].